{
    "clinical_study": {
        "@rank": "97556", 
        "arm_group": [
            {
                "arm_group_label": "BALM ARM", 
                "arm_group_type": "Experimental", 
                "description": "The product will be applied throughout the body in abundant quantity to achieve that the skin be perfectly hydrated. Will be applied twice a day (after showering and at night), massaging the area until completely absorption."
            }, 
            {
                "arm_group_label": "PLACEBO ARM", 
                "arm_group_type": "Placebo Comparator", 
                "description": "It be applicated in like manner that balm arm"
            }
        ], 
        "brief_summary": {
            "textblock": "Capecitabine is a drug that produces dermatologic toxicity frequently  (palmoplantar\n      erythrodysesthesia, rash , alopecia , erythema , dryness, pruritus, hyperpigmentation ,\n      rash, peeling , dermatitis , abnormal pigmentation, and less often blistering, skin ulcers ,\n      photosensitivity reactions, swelling of the face and purple) . The impact in patients'\n      quality of life is great, so We had decided to conduct a randomized clinical trial to\n      evaluate the effectiveness Mary D' uol  balm preventing dermatologic toxicity in patient\n      treated with capecitabine .\n\n      Design: Randomized clinical trial phase II, in parallel and double-blind groups\n\n      Target population : Patients with colon cancer stage II or III ( Dukes' C ) , who will\n      initiate treatment with capecitabine monotherapy.\n\n      Inclusion criteria: Over 18 years, II or III colon (Dukes' C) colon cancer,  primary\n      diagnosis, capecitabine monotherapy, sign the informed consent.\n\n      Primary endpoint: Dermatologic toxicity (yes / no) Statistical analysis: The primary\n      endpoint (percentage of patients that develop dermalogic toxocity in both groups) will be\n      analyzed  by a logistics regression model"
        }, 
        "brief_title": "MARY D'UOL REPAIR BALM IN THE PREVENTION OF SKIN TOXICITY BY CAPECITABINE", 
        "completion_date": {
            "#text": "January 2015", 
            "@type": "Anticipated"
        }, 
        "condition": "Dermatologic Toxiciy Due to Capecitabine", 
        "eligibility": {
            "criteria": {
                "textblock": "Inclusion Criteria:\n\n          -  Over 18 years.\n\n          -  II or III colon cancer (Dukes' C)\n\n          -  Primary diagnosis.\n\n          -  Capecitabine monotherapy\n\n          -  Sign the informed consent\n\n        Exclusion Criteria:\n\n          -  Patients who have received chemotherapy and/or radiotherapy or other treatment\n             adjunct to surgery.\n\n          -  Patients with neoadjuvant chemotherapy"
            }, 
            "gender": "Female", 
            "healthy_volunteers": "No", 
            "maximum_age": "N/A", 
            "minimum_age": "N/A"
        }, 
        "enrollment": {
            "#text": "100", 
            "@type": "Anticipated"
        }, 
        "firstreceived_date": "January 14, 2014", 
        "has_expanded_access": "No", 
        "id_info": {
            "nct_id": "NCT02036957", 
            "org_study_id": "MD-01"
        }, 
        "intervention": {
            "arm_group_label": [
                "BALM ARM", 
                "PLACEBO ARM"
            ], 
            "description": "The product will be applied throughout the body in abundant quantity to achieve that the skin be perfectly hydrated. The product will be applied twice a day (after showering in the morning and at night), massaging the area until completely absorption. Treatment will last three months, and at this time, We will measure toxicologic toxicity in both arms.", 
            "intervention_name": "BALM OR PLACEBO APPLICATION", 
            "intervention_type": "Drug"
        }, 
        "intervention_browse": {
            "mesh_term": "Capecitabine"
        }, 
        "is_fda_regulated": "No", 
        "keyword": [
            "capecitabine", 
            "dermatologic toxicity"
        ], 
        "lastchanged_date": "January 14, 2014", 
        "location": {
            "contact": {
                "last_name": "Arantza S\u00e1ez de Lafuente, Msc", 
                "phone": "945007413"
            }, 
            "facility": {
                "address": {
                    "city": "Vitoria-Gasteiz", 
                    "country": "Spain", 
                    "state": "\u00c1lava", 
                    "zip": "01003"
                }, 
                "name": "Araba University Hospital"
            }, 
            "investigator": [
                {
                    "last_name": "Arantza Saez de Lafuente, Msc", 
                    "role": "Sub-Investigator"
                }, 
                {
                    "last_name": "Raquel Cobos, Msc", 
                    "role": "Sub-Investigator"
                }, 
                {
                    "last_name": "Patricia Seaone, MD", 
                    "role": "Principal Investigator"
                }
            ], 
            "status": "Not yet recruiting"
        }, 
        "location_countries": {
            "country": "Spain"
        }, 
        "number_of_arms": "2", 
        "official_title": "EFFECTIVENESS OF OF MARY D'UOL REPAIR BALM TO PREVENT THE SKIN TOXICITY IN PATIENTS WITH CAPECITABINE. RANDOMIZED CLINICAL TRIAL", 
        "overall_contact": {
            "last_name": "Patricia Seaone, MD", 
            "phone": "945007000"
        }, 
        "overall_official": [
            {
                "affiliation": "Basque Health Service (Research Unit)", 
                "last_name": "Arantza S\u00e1ez de la Fuente, Msc", 
                "role": "Study Chair"
            }, 
            {
                "affiliation": "Basque Health Service (Research Unit)", 
                "last_name": "Patricia Seaone, MD", 
                "role": "Principal Investigator"
            }, 
            {
                "affiliation": "Basque Health Service (Research Unit)", 
                "last_name": "Raquel Cobos, Msc", 
                "role": "Study Chair"
            }
        ], 
        "overall_status": "Not yet recruiting", 
        "oversight_info": {
            "authority": "Spain: Ethics Committee", 
            "has_dmc": "No"
        }, 
        "phase": "Phase 1/Phase 2", 
        "primary_completion_date": {
            "#text": "September 2014", 
            "@type": "Anticipated"
        }, 
        "primary_outcome": {
            "description": "Compare the percentage of patients who develop dermatologic toxicity in any grade (1-5) between intervention and control group at three months of starting treatment, through CTCAE scale (National Cancer Institute Common Toxicity Criteria).", 
            "measure": "Percentage of patients who develop dermatologic toxicity.", 
            "safety_issue": "Yes", 
            "time_frame": "3 moths"
        }, 
        "required_header": {
            "download_date": "ClinicalTrials.gov processed this data on June 04, 2014", 
            "link_text": "Link to the current ClinicalTrials.gov record.", 
            "url": "http://clinicaltrials.gov/show/NCT02036957"
        }, 
        "responsible_party": {
            "investigator_affiliation": "Basque Health Service", 
            "investigator_full_name": "Patricia Seoane", 
            "investigator_title": "oncologist physician", 
            "responsible_party_type": "Principal Investigator"
        }, 
        "secondary_outcome": [
            {
                "description": "Compare the percentage of patients in both groups who required pharmacological treatment to mitigate the dermatologic toxicity produced by chemotherapy", 
                "measure": "Need of pharmacological treatment to mitigate toxicity", 
                "safety_issue": "Yes", 
                "time_frame": "3 months"
            }, 
            {
                "description": "Compare the quality of life in both groups at three months, through the Skindex 29 scale  to evaluate the quality of life due to skin disease.", 
                "measure": "Quality of life", 
                "safety_issue": "No", 
                "time_frame": "3 months"
            }
        ], 
        "source": "Basque Health Service", 
        "sponsors": {
            "lead_sponsor": {
                "agency": "Basque Health Service", 
                "agency_class": "Other"
            }
        }, 
        "start_date": "February 2014", 
        "study_design": "Allocation: Randomized, Endpoint Classification: Safety Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Investigator), Primary Purpose: Prevention", 
        "study_type": "Interventional", 
        "verification_date": "January 2014"
    }
}